Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renexin CR + aspirin
- Development stage
- Unknown
- Lead developer
- SK Chemicals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Renexin CR + aspirin is a **fixed-dose combination oral therapy** consisting of Renexin CR (a controlled-release formulation that typically combines cilostazol and ginkgo biloba extract) plus aspirin (acetylsalicylic acid). This combination is investigated primarily for **secondary prevention in acute non-cardioembolic ischemic stroke**. Mechanistically, **aspirin inhibits platelet aggregation via irreversible inhibition of cyclooxygenase-1 and cyclooxygenase-2, thereby reducing thromboxane A2 synthesis and platelet activation**. Renexin CR's components add additional **antiplatelet (cilostazol, a phosphodiesterase-3 inhibitor increasing cAMP in platelets and vasculature)** and **vasodilatory/antioxidant (ginkgo biloba extract) effects**. The combination is designed to enhance antithrombotic efficacy while potentially minimizing bleeding risk compared to traditional dual antiplatelet regimens[1][5].
- Brand names
- Renexin CR + aspirin
- Other names
- Renexin CR plus aspirin
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Renexin CR + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renexin CR + aspirin.